The life sciences industry knows that government enforcement actions offer critical insights into emerging legal and compliance risks that may impact their business. In 2020, there were several key enforcement actions that are essential to know to ensure that your business operations continue to address operational risks. In this session, we will discuss key areas of government enforcement from key 2020 investigations and settlements, including areas of government scrutiny and legal theories underlying these actions. We will gleam insights from government complaints and settlement agreements, as well as OPDP enforcement letters. We also will discuss emerging trends in corporate integrity agreements arising from these matters, and discuss the outlook in industry enforcement for 2021.